INTRODUCTION Cardiovascular disease is the most common cause of death and morbidity in patients with end-stage renal disease. Sacubitril/valsartan (SAC/VAL) can reduce the risk of cardiovascular mortality among patients with heart failure (HF). The present study set out to evaluate the efficacy of SAC/VAL in the treatment of patients with HF with preserved ejection fraction (HFpEF) undergoing peritoneal dialysis (PD) (HFpEF&PD). METHODS A total of 160 patients with HFpEF&PD were enrolled and randomly divided into the control group (N = 80) and SAC/VAL group (N = 80). The cardiac function efficacy, HF scoring efficacy, echocardiographic parameters, serological indicators, and 6-minute walking test were compared before and after treatment. RESULTS After 6 months of treatment, the total number of patients who responded to treatment in the SAC/VAL group was higher than that of the control group in terms of cardiac function and HF scoring efficacy. After treatment, levels of early diastolic/late diastolic filling velocity and left ventricular ejection fraction were increased in both groups, while the levels of left atrial diameter, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, inter-ventricular septal diameter, and left ventricular posterior wall diameter were decreased; the NT-proBNP levels were diminished in both groups, while hemoglobin levels and the 6-minute walk distance were increased; the systolic blood pressure, diastolic blood pressure, and 24-h ultrafiltration volume were lowered in all patients. The changes in these indexes in the SAC/VAL group were more obvious than those in the controls. CONCLUSION SAC/VAL can significantly improve cardiac function in patients with HFpEF&PD.

中文翻译：

---

沙库巴曲/缬沙坦对腹膜透析保留射血分数的心力衰竭患者的疗效研究。

简介 心血管疾病是终末期肾病患者死亡和发病的最常见原因。沙库巴曲/缬沙坦（SAC/VAL）可以降低心力衰竭（HF）患者心血管死亡的风险。本研究旨在评估 SAC/VAL 治疗射血分数保留的心力衰竭 (HFpEF) 腹膜透析 (PD) 患者 (HFpEF&PD) 的疗效。方法 160例HFpEF&PD患者随机分为对照组（N=80）和SAC/VAL组（N=80）。比较治疗前后心功能疗效、心力衰竭评分疗效、超声心动图参数、血清学指标、6分钟步行试验。结果治疗6个月后，SAC/VAL组治疗有反应的患者总数在心功能和心力衰竭评分疗效方面均高于对照组。治疗后，两组舒张早/舒张末期充盈速度、左心室射血分数水平均升高，而左心房内径、左心室舒张末期内径、左心室收缩末期内径、室间隔直径水平均升高。 ，左心室后壁直径减小；两组的 NT-proBNP 水平均下降，而血红蛋白水平和 6 分钟步行距离均增加；所有患者的收缩压、舒张压和24小时超滤量均降低。SAC/VAL组这些指标的变化较对照组更为明显。结论 SAC/VAL可显着改善HFpEF&PD患者的心功能。